policy

Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } đź“ş BHF Data Science Centre seminar by Dr Samantha Ip & Dr Hoda Abbasizanjani

COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } Twitter thread summarising key results

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } Twitter thread

Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } đź“ş BHF Data Science Centre seminar by Dr Samantha Ip & Dr Hoda Abbasizanjani

Understanding COVID-19 trajectories from a nationwide linked electronic health record cohort of 56 million people: phenotypes, severity, waves & vaccination

âť— Now published in The Lancet Digital Health Johan H Thygesen, Chris Tomlinson, Sam Hollings, Mehrdad Mizani, Alex Handy, Ashley Akbari, Amitava Banerjee, Jennifer Cooper, Alvina Lai, Ken Li, Bilal Mateen, Naveed Sattar, Reecha Sofat, Ana Torralbo, Honghan Wu, Angela Wood, Jonathan A C Sterne, Christina Pagel, William Whiteley, Cathie Sudlow, Harry Hemingway, Spiros Denaxas, on behalf of the CVD-COVID-UK Consortium (2022).

Vaccinating adolescents against SARS-CoV-2 in England: a risk–benefit analysis

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } Twitter thread by Deepti Gurdasani

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort

âť— Now published in Heart Alex Handy, Amitava Banerjee, Angela Wood, Caroline Dale, Cathie Sudlow, Chris Tomlinson, Daniel Bean, Johan H Thygesen, Mehrdad A Mizani, Michail Katsoulis, Rohan Takhar, Sam Hollings, Spiros Denaxas, Venexia Walker, Richard Dobson, Reecha Sofat & CVD-COVID-UK Consortium (2022).

Vaccinating adolescents in England: a risk-benefit analysis

âť— Now published in The Journal of the Royal Society of Medicine (JRSM) Gurdasani D, Bhatt S, Costello A, Denaxas S, Flaxman S, Greenhalgh T, Griffin S, Hyde Z, Katzourakis A, McKee M, Michie S, Ratmann O, Reicher S, Scally G, Chris Tomlinson, Yates C, Ziauddeen H & Pagel C (2021).